Lilly’s next-gen obesity drug shows weight loss potential but safety signals need more data
TL;DR
Lilly’s obesity drug retatrutide, which previously showed rapid weight loss and diabetes benefits, yielded new safety data at the ADA meeting and in Lancet: in TRANSCEND-T2D-1, 7 of 403 participants on retatrutide had arrhythmias and 3 had major cardiovascular events versus none on placebo, a small event count that experts say is insufficient to draw firm cardiovascular risk conclusions.
- Lilly shares safety, tolerability data on its next-gen obesity drug statnews.com
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters
- A new wave of weight-loss therapies aims to be better than today’s GLP-1s MarketWatch
- ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech
Want the full story? Read the original reporting
Read on statnews.com